Skip to content

Single-scan Rest/Stress Imaging With Cadmium Zinc Telluride-based SPECT for Coronary Flow Quantification

Single-scan Rest/Stress Imaging With Cadmium Zinc Telluride-based SPECT for Coronary Flow Quantification

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02985931
Enrollment
30
Registered
2016-12-07
Start date
2012-05-31
Completion date
2015-05-31
Last updated
2016-12-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Quantitative Analysis of SPECT MPI

Brief summary

The investigators aim to address this issue with novel image quantification methods using CZT-based SPECT, which is capable of dynamic data acquisition and therefore feasible for the quantification of the coronary flow. The investigators will use kinetic modeling techniques to design a study that allows the absolute flow quantification. To make this study practical, the investigators will develop a protocol that includes the acquisition of both the rest and stress scan within the same scan that is shorter than 30 minutes. The SPECT-measured flow will be validated against the flow measured with cardiac MRI scans. Patients with high CAD risk will be recruited for the clinical trial. Data from these human subjects will be used for determination of the performance of the developed algorithm. With the proposed rapid scan with absolute quantification capabilities, the investigators expect to increase the diagnosis accuracy while maintaining the patient throughput.

Interventions

OTHERDiagnostic imaging scans of SPECT and MRI

Sponsors

Chang Gung Memorial Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Subjects with high possibility of coronary artery disease after being evaluated by a cardiologist. 2. \> 20 years old. 3. Not under infection or other conditions inappropriate for being recruited. 4. Without myocardial infarction within one week. 5. With stable blood pressure. 6. Subjects with normal kidney functions and without allergic reactions to MRI contrast agents.

Exclusion criteria

1. Subjects who cannot take a SPECT scan or do not agree to sign the informed consent. 2. Pregnant subjects or subjects who are currently breast-feeding. 3. Those currently under radiation therapies. 4. Patients with pleural effusion. 5. Patients who are allergic to SPECT tracers. 6. Patients with serious psychological disorders. 7. Patients with asthma. 8. Patients with stroke within a week. 9. Patients with AV block. 10. Patients with sinus syndrome. 11. Subjects who are currently under other clinical trials. 12. Subjects with poor kidney functions who are inappropriate for MRI contrast agents. 13. Subjects with pacemakers. 14. Subjects with Claustrophobia. 15. Subjects who cannot hold breath for cardiac MRI studies.

Design outcomes

Primary

MeasureTime frame
Correlation between SPECT- and MRI-measured flow valuesthrough study completion, an average of 3 year

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026